CN109865050A - A kind of Chinese medicine composition and application thereof for inhibiting liver cancer - Google Patents
A kind of Chinese medicine composition and application thereof for inhibiting liver cancer Download PDFInfo
- Publication number
- CN109865050A CN109865050A CN201910234285.8A CN201910234285A CN109865050A CN 109865050 A CN109865050 A CN 109865050A CN 201910234285 A CN201910234285 A CN 201910234285A CN 109865050 A CN109865050 A CN 109865050A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine composition
- liver cancer
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine compositions and application thereof for inhibiting liver cancer, the component of the Chinese medicine composition is as follows: centellaing asiatica 9-25 parts, 9-15 parts of dandelion, 9-15 parts of black nightshade, 10-20 parts of lobelia chinensis, 10-20 parts of oldenlandia diffusa, 10-20 parts of Prunella vulgaris, 10-20 parts of Tupistra, 5-15 parts of adjuvant.Understanding the present invention is based on Chinese medicine to onset of liver cancer principle, in conjunction with unique pharmacological effect of traditional Chinese medicine, the Chinese medicine composition of offer can be effective for inhibiting liver cancer, for being not suitable for operative treatment, it is also effective in cure to hair disease such as jaundice, ascites, pain etc. while effectively inhibiting cancer or to the patient for not being resistant to Radiotherapy chemotherapy, life in patients can be significantly improved, life cycle is extended.
Description
Technical field
The present invention relates to a kind of Chinese medicine compositions, and in particular to a kind of for inhibiting the Chinese medicine composition and its use of liver cancer
On the way.
Background technique
Malignant tumour (cancer) is the major disease that a kind of death rate is high, life cycle is short, the in recent years morbidity of malignant tumour
Rate and lethality are in rising trend, seriously endanger the health and lives of the mankind.It is most for the treatment of tumor patient at present
Using operative treatment combination Radiotherapy chemotherapy method, still, this method is larger to the physical trauma of patient, and medical expense is high, and
Curative effect is unsatisfactory.
Cancer belongs to the scope of " addiction block ", " liver product " in traditional Chinese medicine, and mostly because of disorder of emotion, injury due to diet, exopathogen enemy intrusion or invasion is such as
Caused by hepatitis B, liver and spleen are impaired, internal organs are become estranged.Chinese medicine thinks that exopathogen invades body, and good and evil are crossed swords and internal zang-fu differentiation,
Ascending or descending movement of vital Qi is not normal, qi stagnation hemagglutination, stasis blocking train of thought, agglomerates blocking.Liver cancer is that the death rate is only second to gastric cancer, the third-largest evil of lung cancer
Property tumour.
The treatment of liver cancer mainly uses local treatment, including TACE (transcatheter arterial at present
Chemoembolization, transcatheter arterial chemoembolization) art, PEI (Percutaneous Ethanol Injection
Therapy, percutaneous Ethanol Injection therapy), radio-frequency ablation procedure, radiotherapy and operative treatment etc..Various treatment methods are all
There are its advantage and disadvantage and indication, and has different degrees of side effect.Such as TACE postoperative patient often merges fever, pain, vomits
It spits and liver dysfunction, postoperative quality of life is low, and physical function is remarkably decreased, and immunity reduces.TACE art, PEI, RF ablation
Art, fractionated radiation treatments and operative treatment can all cause liver dysfunction to some extent, and cirrhosis is further aggravated.To postoperative
In the case that body items function is all not so good, postoperative quality of life how is improved, extends life cycle, reduce recurrence rate and become liver
It is also problem that whether cancer treatment is successfully crucial.
The pathogenesis of liver cancer is sufficiently complex, and medical field is still being explored, and onset concealment, early stage there is not disease generally
Shape, consequently found that being many places in middle and advanced stage, not every patient is suitable for operative treatment, and only cardio-pulmonary function is preferable, tumour
The patient not shifted is just suitble to operation.Liver cancer, which merges cirrhosis, to be caused to limit to local surgical treatment, for being not suitable for operation
Or for the similar unsuitable patient of local surgical treatment scheme, effective Regimen with Traditional Chinese Medicine has original advantage.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine compositions, provide a kind of new way effectively to inhibit, treating liver cancer, subtract
The pain of light patient, extends the life cycle of patient, reduces recurrence rate, and improve the life quality of patient.
In order to achieve the above object, the present invention provides a kind of for inhibiting the Chinese medicine composition of liver cancer, the Chinese traditional medicine composition
The component of object is as follows: it centellas asiatica 9-25 parts, 9-15 parts of dandelion, and 9-15 parts of black nightshade, 10-20 parts of lobelia chinensis, oldenlandia diffusa 10-
20 parts, 10-20 parts of Prunella vulgaris, 10-20 parts of Tupistra, 5-15 parts of adjuvant.
Preferably, the adjuvant includes: for the component A of tonifying Qi, component A be selected from ginseng (or Radix Codonopsis), Radix Astragali and
Any one in Radix Glycyrrhizae or any a variety of combination.
Preferably, the adjuvant includes: the component B for enriching blood, component B select Chinese herbaceous peony or Radix Angelicae Sinensis.
Preferably, the adjuvant includes: the component C stagnant for relieving stagnant Qi, component C select betel nut, Fructus Aurantii, Cortex Magnoliae Officinalis and purple
Any one in Soviet Union or any a variety of combination.
Preferably, the adjuvant includes: selecting Rhizoma Chuanxiong and/or the root of Dahurain angelica for the component D of promoting blood circulation, component D.
Preferably, the adjuvant includes: for carry all medicine of row and be ships component E, component E selects campanulaceae.
Preferably, the auxiliary material is by the ginseng of equal portions, Radix Astragali, Radix Glycyrrhizae, Chinese herbaceous peony, betel nut, Fructus Aurantii, Cortex Magnoliae Officinalis, purple perilla, river
Rhizome of chuanxiong, the root of Dahurain angelica and campanulaceae are constituted.
Preferably, the Chinese medicine composition is in tablet, pill, capsule or electuary.
The present invention also provides a kind of purposes of above-mentioned Chinese medicine composition, which is used to prepare treatment liver cancer
Drug.
In pharmaceutical composition of the invention, monarch drug in a prescription for heat-clearing anticancer detoxify, selection centella asiatica, oldenlandia diffusa, opening
Arrow；Ministerial drug is used for soothing liver-qi stagnation, selects dandelion, black nightshade, lobelia chinensis, Prunella vulgaris；Adjutant is used for tonifying Qi, enriches blood, selection ginseng,
Radix Astragali, Radix Glycyrrhizae, Chinese herbaceous peony；Make in medicine, betel nut, Fructus Aurantii, Cortex Magnoliae Officinalis, purple perilla are all the stagnant product of relieving stagnant Qi, Rhizoma Chuanxiong, root of Dahurain angelica promoting blood circulation, campanulaceae
It carries all medicines of row and is boat volume.Understanding the present invention is based on Chinese medicine to onset of liver cancer mechanism, in conjunction with unique pharmacological effect of traditional Chinese medicine,
The Chinese medicine composition of offer can be effective for inhibiting liver cancer, for unsuitable operative treatment, or to the trouble for not being resistant to Radiotherapy chemotherapy
Person, it is also effective in cure to complication such as jaundice, ascites, pain etc. while effectively inhibiting cancer, survival of patients can be significantly improved
Quality extends life cycle.
Specific embodiment
The following further describes the technical solution of the present invention with reference to embodiments.
Embodiment 1
Centella asiatica 15 grams, 15 grams of dandelion, Tupistra 15g, 12 grams of black nightshade, 15 grams of lobelia chinensis, oldenlandia are weighed respectively
Careless 15 grams, 15 grams of Prunella vulgaris, Rhizoma Chuanxiong, Chinese herbaceous peony, ginseng, Radix Astragali, campanulaceae, the root of Dahurain angelica, betel nut, Cortex Magnoliae Officinalis, Radix Glycyrrhizae, purple perilla, Fructus Aurantii equal portions
It is 9 grams total.
1L pure water is added, boils, keeps 2h or so, naturally cools to 40 DEG C or so, the dregs of a decoction are removed, for taking orally.
Embodiment 2
Centella asiatica 25 grams, 15 grams of dandelion, Tupistra 15g, 15 grams of black nightshade, 20 grams of lobelia chinensis, oldenlandia are weighed respectively
Careless 20 grams, 20 grams of Prunella vulgaris, Rhizoma Chuanxiong, Chinese herbaceous peony, ginseng, Radix Astragali, campanulaceae, the root of Dahurain angelica, betel nut, Cortex Magnoliae Officinalis, Radix Glycyrrhizae, purple perilla, Fructus Aurantii equal portions
It is 15 grams total.
1.5L pure water is added, boils, keeps 4h, filtering, aqueous solution further removes aqueous solvent, obtains paste mixing
Object is added the auxiliary materials such as cyclodextrin, pill is made.
Embodiment 3
Centella asiatica 15 grams, 12 grams of dandelion, Tupistra 20g, 12 grams of black nightshade, 15 grams of lobelia chinensis, oldenlandia are weighed respectively
Careless 15 grams, 15 grams of Prunella vulgaris, Rhizoma Chuanxiong, Chinese herbaceous peony, ginseng, Radix Astragali, campanulaceae, the root of Dahurain angelica, betel nut, Cortex Magnoliae Officinalis, Radix Glycyrrhizae, purple perilla, Fructus Aurantii equal portions
It is 10 grams total.
1L pure water is added, boils, keeps 3h, filtering, aqueous solution further removes aqueous solvent, obtains pasty mixture,
The auxiliary materials such as cyclodextrin are added, pill is made.
60 Patients with Primary are randomly divided into observation group 30 and control group 30.Control group gives conventional control
It treats, Chinese medicine composition of the invention is given on the basis of conventional therapy by observation group, and 1 dose/day divides 2 times and take, and 200ml/ times.
The course for the treatment of is 3 months.The conventional therapy refers to that doctor performs the operation according to the patient's condition of patient, at the necessary treatment means such as chemotherapy
Reason.
1. the general information of patient
The general information such as Gender, age, clinical stages, two groups of no difference of science of statistics, are shown in Table 1.
Table 1: patient's general information
2. TCM syndrome integrates
According to " new Chinese medicine guideline of clinical investigations-primary carcinoma of liver Syndrome Scale quantifies table " of version in 2002.Abdomen
Swollen, dim complexion, body syntexis, dry and hard excrement, mouth be glutinous be not intended to drink, vexed, irritability, jaundice, bitter taste, dry mouth and throat, urinate it is red, send out
Heat, polydipsia, dysphoria in chestpalms-soles, dizzy, tinnitus, the soreness of waist, knee be soft, insomnia, night sweat, bleeding, bulging, blue veins exposure, hypochondriac pain, uncomfortable in chest kind
It heaves a deep sigh, lump in the abdomen, indigestion and loss of appetite, deficiency of food, gastral cavity is bored, be in a very depressed state, belch, Nausea and vomiting, diarrhea, spiritlessness and weakness totally 34 symptoms.
By the nothing of symptom, it is light, in, weight grade scale respectively based on 0,1,2,3 point.It is scored one by one by table the above symptom and calculates total score,
It is denoted as clinical syndrome integral value.
As the result is shown: disease total mark no significant difference, each group are relatively treated after treating before the treatment for control group and observation group
Preceding TCM syndrome total mark reduces, and compares observation group and control group disease total mark after treatment, finds observation group compared with control group
The decline of TCM syndrome total mark becomes apparent from (p < 0.05), illustrates that observation group becomes apparent from compared with the improvement of control group TCM syndrome, is shown in Table 2.
Table 2: control group is compared with the pretherapy and post-treatment TCM syndrome total mark of observation group
| Group | Before treatment | After treatment |
| Control group | 29.83±2.78 | 21.4±5.59 |
| Observation group | 30.30±2.83 | 18.20±5.62 |
3. TCM syndrome curative effect
Improve situation referring to primary carcinoma of liver clinic syndrome in " new Chinese medicine guideline of clinical investigations " to draft.It is effective:
Decline >=70% before clinical syndrome total mark value is relatively treated after treatment；It is effective: before clinical syndrome total mark value is relatively treated after treatment
Decline>=30%, and<70%；It is invalid: decline < 30% before clinical syndrome total mark value is relatively treated after treatment, or even increase.Always have
Efficiency=(effective number of cases+effective number of cases)/total number of cases * 100%.
As the result is shown: observation group is significantly raised compared with control group total effective rate, and difference has statistical significance, is shown in Table 3.
Table 3: control group is compared with observation group's TCM syndrome curative effect
| Group | Number of cases | It is effective | Effectively | In vain | Total effective rate |
| Control group | 30 | 3 (10%) | 15 (50%) | 12 (40%) | 60% |
| Observation group | 30 | 6 (20%)) | 19 (63.3%) | 5 (16.7%) | 83.3% |
4.Karnofsky scoring (KPS scoring): it is evaluated using Karnofsky functional status standards of grading.
As the result is shown: KPS scores no significant difference before the treatment for control group and observation group, before relatively treating after each group treatment
KPS, which scores, to be increased, and compares observation group and control group KPS scoring after treatment, it is found that observation group scores compared with control group KPS and increased (p
< 0.05), illustrate that observation group significantly improves patients ' life quality compared with control group, is shown in Table 4.
Table 4: control group is compared with the pretherapy and post-treatment KPS scoring of observation group
| Group | Before treatment | After treatment |
| Control group | 66.90±3.87 | 73.87±3.36 |
| Observation group | 66.37±3.24 | 82.07±4.15 |
5. alpha-fetoprotein (alpha fetoprotein, AFP), carcinomebryonic antigen (carcinoembryonic antigen,
CEA) horizontal
As the result is shown: control group and observation group AFP, CEA no significant difference before the treatment, before relatively being treated after each group treatment
AFP, CEA are reduced, and compare observation group and control group A FP, CEA after treatment, and discovery observation group declines journey compared with control group A FP, CEA
Degree is bigger, and difference has statistical significance (p < 0.05), is shown in Table 5.
Table 5: control group and observation group pretherapy and post-treatment AFP, CEA are horizontal
6. adverse reaction
Two groups are showed no obvious adverse reaction.
In conclusion Chinese medicine composition provided by the invention can effectively inhibit liver cancer, and it is significant in efficacy, patient can be effectively improved
Life quality, extend life cycle.
It is discussed in detail although the contents of the present invention have passed through above preferred embodiment, but it should be appreciated that above-mentioned
Description is not considered as limitation of the present invention.After those skilled in the art have read above content, for of the invention
A variety of modifications and substitutions all will be apparent.Therefore, protection scope of the present invention should be limited to the appended claims.
Claims (9)
1. a kind of for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the component of the Chinese medicine composition is as follows: 9- of centellaing asiatica
It 25 parts, 9-15 parts of dandelion, 9-15 parts of black nightshade, 10-20 parts of lobelia chinensis, 10-20 parts of oldenlandia diffusa, 10-20 parts of Prunella vulgaris, opens
10-20 parts of arrow, 5-15 parts of adjuvant of mouth.
2. as described in claim 1 for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the adjuvant includes: using
In the component A of tonifying Qi, any one or any a variety of combination of the component A in ginseng, Radix Codonopsis, Radix Astragali and Radix Glycyrrhizae.
3. as described in claim 1 for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the adjuvant includes: using
Chinese herbaceous peony or Radix Angelicae Sinensis are selected in the component B to enrich blood, component B.
4. as described in claim 1 for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the adjuvant includes: using
Any one in betel nut, Fructus Aurantii, Cortex Magnoliae Officinalis and purple perilla or any a variety of combination are selected in the component C that relieving stagnant Qi is stagnant, component C.
5. as described in claim 1 for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the adjuvant includes: using
Rhizoma Chuanxiong and/or the root of Dahurain angelica are selected in the component D of promoting blood circulation, component D.
6. as described in claim 1 for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the adjuvant includes: using
The all medicines of Yu Zaihang and be ships component E, component E select campanulaceae.
7. as described in claim 1 for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the auxiliary material is by equal portions
Ginseng, Radix Astragali, Radix Glycyrrhizae, Chinese herbaceous peony, betel nut, Fructus Aurantii, Cortex Magnoliae Officinalis, purple perilla, Rhizoma Chuanxiong, the root of Dahurain angelica and campanulaceae are constituted.
8. as described in claim 1 for inhibiting the Chinese medicine composition of liver cancer, which is characterized in that the Chinese medicine composition is in
Tablet, pill, capsule or electuary.
9. a kind of purposes of Chinese medicine composition described in any one of -8 according to claim 1, which is characterized in that the Chinese medicine group
Close the drug that object is used to prepare treatment liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910234285.8A CN109865050B (en) | 2019-03-26 | 2019-03-26 | Traditional Chinese medicine composition for inhibiting liver cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910234285.8A CN109865050B (en) | 2019-03-26 | 2019-03-26 | Traditional Chinese medicine composition for inhibiting liver cancer and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109865050A true CN109865050A (en) | 2019-06-11 |
| CN109865050B CN109865050B (en) | 2021-07-30 |
Family
ID=66921241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910234285.8A Active CN109865050B (en) | 2019-03-26 | 2019-03-26 | Traditional Chinese medicine composition for inhibiting liver cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109865050B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491740A (en) * | 2014-12-31 | 2015-04-08 | 黑龙江中医药大学 | Traditional Chinese medicine composition for treating liver cancer and preparation method of traditional Chinese medicine composition |
-
2019
- 2019-03-26 CN CN201910234285.8A patent/CN109865050B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491740A (en) * | 2014-12-31 | 2015-04-08 | 黑龙江中医药大学 | Traditional Chinese medicine composition for treating liver cancer and preparation method of traditional Chinese medicine composition |
Non-Patent Citations (4)
| Title |
|---|
| 叶丽红 等: "原发性肝癌的中医治则与治法探讨", 《南京中医药大学学报》 * |
| 周燏: "积雪草总苷抗肿瘤作用及机制研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 常敏毅 编著: "《实用抗癌方剂》", 31 October 1998, 中国医药科技出版社 * |
| 晏传奇 等: "开口箭提取物对小鼠移植性实体瘤H22的抑制作用", 《江苏中医药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109865050B (en) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103536638A (en) | Medicament for treating gastrointestinal dysfunction and preparation method thereof | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN104491755A (en) | Traditional Chinese medicine composition for treating abdominal distension and preparation method of traditional Chinese medicine composition | |
| CN102614442B (en) | Traditional Chinese drug capsules with effects of immunity enhancing, blood reinforcing and antiemesis | |
| CN103550506B (en) | A kind of in radiotherapy with the use of Chinese medicine composition | |
| CN103505698A (en) | Traditional Chinese medicine composition for treating malignant lymphoma | |
| WO2024099339A1 (en) | Traditional chinese medicine composition and use thereof | |
| CN108635544A (en) | Treat Hashimoto's thyroiditis Chinese medicine composition and its preparation method and application | |
| CN111671864A (en) | Traditional Chinese medicine preparation for relieving bone marrow suppression caused by chemotherapy and preparation method thereof | |
| CN104324331A (en) | Lung tumor suppression cream applied to Qi-stagnation and blood stasis and preparation method of lung tumor suppression cream | |
| CN104491291A (en) | Traditional Chinese medicine composition for treating liver-yang hyperactivity type thyroid adenoma | |
| CN109865050A (en) | A kind of Chinese medicine composition and application thereof for inhibiting liver cancer | |
| CN106177807A (en) | A kind of Chinese medicine formula treating breast carcinoma | |
| CN104225395A (en) | Tumor-resistant traditional Chinese medicine and preparation method | |
| CN113144108A (en) | A Chinese medicinal composition for treating coronavirus and preparation method thereof | |
| CN101708270B (en) | Traditional Chinese medicine composition for detoxicating and fighting cancer | |
| CN105147994A (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof | |
| CN104398975A (en) | Traditional Chinese medicinal preparation for treating fibroadenoma of breast and preparation method thereof | |
| CN115089663B (en) | Traditional Chinese medicine composition with qi-tonifying and body fluid-generating effects and preparation method thereof | |
| CN102961704A (en) | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof | |
| CN102755560B (en) | Traditional Chinese medicine compound reducing chemotherapy side reaction and preparation method and application thereof | |
| CN105395883A (en) | Traditional Chinese medicine for curing anemia | |
| CN111481649A (en) | External traditional Chinese medicine composition for treating breast cancer and preparation method thereof | |
| CN104721786A (en) | Traditional Chinese medicine preparation for treating intrahepatic cholestasis of pregnancy and preparation method of traditional Chinese medicine preparation | |
| CN105169348A (en) | Traditional Chinese medicine preparation for promoting pancreas incision drainage postoperative rehabilitation and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |